“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

Because SGLT2 inhibitors act on the kidney, and the amount of glucose excreted is closely dependent on the glomerular filtration rate (GFR), it can be anticipated that SGLT2 inhibitors will have a ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

[1] The purpose of this review paper is to analyze the role of the kidney in glucose homeostasis, emphasizing in SGLT2 inhibition as a new therapeutic target for diabetes management. placebo ...

Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. SGLT2 inhibitors were also linked to reduced amputation and AKI risks. Use of SGLT2 inhibitors was ...

The study offers promising news for people with type 2 diabetes. By using SGLT2 inhibitors, they may be able to lower their ...

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

Teams of researchers are investigating empagliflozin and dapagliflozin in patients with autosomal dominant polycystic kidney disease (AD PKD).

New research shows diabetes medication SGLT-2 inhibitors lower dementia risk by up to 35%, offering hope for millions ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones,” Dr Fuster’s team concluded. Other study findings indicate the ...

SGLT2 inhibitors significantly improves kidney health in a diverse group of Asian adults with Type 2 diabetes, study finds.